Sixfold Bioscience LTD.

INDUCE aims to develop and validate Sixfold's RNA therapeutics delivery system, MergoⓇ, for delivery of (simultaneously developed) short-interfering RNA (siRNA) gene silencing cargo to a specific tissue type (undisclosed). INDUCE brings together multidisciplinary, high-expertise partners with a track record of successful project completion, allowing for b...

Sixfold Bioscience, a London-based biotech SME, are developing MergoⓇ, RNA-based delivery systems designed to carry oligonucleotides therapeutics to extrahepatic tissues. The MergoⓇ technology allows the development of a platform that can rapidly be engineered to explore and screen a large and diverse chemical space. Indeed, Mergos can be easily chemicall...

ENHANCE aims to improve the development and manufacturing process of Sixfold's innovative Mergo(r) formulations for the delivery of siRNA therapeutics to diseased cells. ENHANCE combines multidisciplinary partners with highly complementary expertise and successful project delivery experience, with rapid scientific and commercial progress. Compared to smal...

SUMMIT aims to develop and validate Sixfold's oligonucleotide delivery system, MergoⓇ, for delivery of (simultaneously developed) short-interfering RNA (siRNA) gene silencing cargo to a specific tissue type (undisclosed). SUMMIT combines multidisciplinary partners with highly complementary expertise and experience in delivering successful projects, with r...

TARGET aims to preclinically validate Sixfold's Programmable Oligonucleotide Delivery System, Mergo, for delivery of short-interfering RNA (siRNA) gene silencing cargo to specific cells. By taking advantage of the interdisciplinary and complementary expertise of the partners --Sixfold and Medicine Discovery Catapult (MDC)-- the project allows for rapid sc...

The ability of RNA to assemble into nanoparticles of different sizes and shapes has been exploited by academic and industrial research groups for drug delivery. In this project, the expertise of the candidate will be **combined** with **Sixfold Bioscience PODS and the robotic platforms in ROAR to develop a customised self-assembled RNA nanoparticle for ca...

RAPOD aims to expand the drug delivery capabilities of Sixfold's Programmable Oligonucleotide Delivery System (PODS) for delivery of short-interfering RNA (siRNA) gene silencing cargo to specific cancer cells by increasing therapeutic loading capacity. By taking advantage of the interdisciplinary and complementary expertise of the partner/subcontractor --...

To develop novel, safe and effective methods for systemic delivery of messenger RNA gene therapeutic cargo to specific cells.

TARGET aims to preclinically validate Sixfold's Programmable Oligonucleotide Delivery System (PODS) for delivery of short interfering RNA (siRNA) gene silencing cargo to specific cells. By taking advantage of the interdisciplinary and complementary expertise of the partners --Sixfold and Medicine Discovery Catapult (MDC)-- the project allows for rapid sci...

Awaiting Public Project Summary

While traditional pharmaceutical development of small-molecule and protein-based therapeutics can take years to reach patients, a more agile multi-disciplinary approach based on gene therapies has the potential to not only reduce time to market, but also improve therapeutic outcomes and reduce cost. This ability to rapidly engineer gene therapies has been...